Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...
A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...
Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Semaglutide was a top-selling drug in 2023, and its popularity only continues to grow, as it’s been increasingly prescribed off-label for weight loss. Read on to learn more about Ozempic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results